Köhnlein T, Schmidt-Scherzer K, Greulich T, Bals R
Klinikum St. Georg gGmbH Leipzig, Robert-Koch-Klinik.
Wilhelminenspital Wien, 2. Medizinische Abteilung/Lungenabteilung.
Pneumologie. 2014 Jul;68(7):492-5. doi: 10.1055/s-0034-1365802. Epub 2014 Jul 9.
Augmentation therapy in Alpha-1 Antitrypsin Deficiency aims to reduce the progression of lung emphysema, to reduce exacerbation frequency, and to improve quality of life. This expert statement briefly summarizes the most important treatment studies performed in patients with Alpha-1 Antitrypsin Deficiency and severe lung emphysema. Indications and contraindications for long-term intravenous augmentation therapy with human Alpha-1 Antitrypsin are derived from the available study results. Safety issues and the controversies of this topic are discussed in detail.
α-1抗胰蛋白酶缺乏症的增强治疗旨在减缓肺气肿的进展、降低急性加重频率并改善生活质量。本专家声明简要总结了针对α-1抗胰蛋白酶缺乏症和重度肺气肿患者开展的最重要的治疗研究。人α-1抗胰蛋白酶长期静脉增强治疗的适应证和禁忌证源自现有的研究结果。本文详细讨论了该主题的安全性问题及争议。
